© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Scientists in Japan first brought Nafamostat Methanesulfonate to the lab in the 1970s, looking for a tool to control excessive blood clotting. Drug developers wanted to give patients something safer than older treatments with fewer side effects, especially during procedures like kidney dialysis where clots show up out of nowhere and put lives at risk. Clinical teams spent years observing how this compound performed inside and outside the hospital. As experience grew, doctors saw its value expand beyond the early ideas, setting the stage for a molecule that would later pop up in unexpected places, from ICUs to basic research. The slow grind of bench work and clinical trials carved out small but important windows for a drug that still anchors itself on a careful scientific past.
Nafamostat Methanesulfonate shows up on pharmacy shelves as a synthetic serine protease inhibitor, mostly in white or nearly white powder form. Hospitals rely on it for its short half-life and predictable effects, which makes it a favorite for tightly controlled applications, where rapid adjustment keeps patients safer. Chemists bind the active compound to the methanesulfonate group, boosting stability and making it easier to prepare for patient use. Clinicians have gotten to know its quick onset and short duration, which shaves down risks in sudden bleeding or clotting situations. Its origins in Japanese medical innovation earned it several trade names, each familiar to those who rely on this class of anticoagulants day and night.
This compound doesn’t waste any time breaking down in the human body. It carries a molecular formula of C21H25N5O8S2 with a molar mass tipping the scales at 539.6 g/mol. At room temperature, it holds steady as a crystalline solid. It blends well with water, thanks to its salt form, but holds back in organic solvents — a useful bit of chemistry that allows for clear, simple administration in clinical environments. Researchers who handle it in the lab keep an eye on storage, using cool, dry places to prevent degradation. Anyone who’s worked behind the scenes with this molecule knows its signature reactivity and the steady, sharp odor it carries when not handled with care.
Each vial or ampoule of Nafamostat Methanesulfonate comes with meticulous information. Labels show the specific active ingredient in milligrams, batch identifiers, expiration dates, and safety marks. Chemical analysis guarantees purity levels above 98%, flagged by regular checks using high-performance liquid chromatography. The pharmaceutical grade material must pass stringent testing for pH range, solubility, and particulate matter, reflecting strict trust in quality. Labels include cautionary statements, urging proper storage and warning about the dangers of improper use, to ensure that practitioners don’t run into trouble with dosing or handling.
Chemists lock down a multi-stage synthesis route. Work starts with benzamidine derivatives matched with naphthylamines, bringing the backbone together under controlled temperatures. A painstaking series of reactions add the methanesulfonate salt group, a step that cements stability and improves handling. Each reaction step involves strict purification, often with column chromatography and crystallization, weeding out residues and byproducts that could put patients at risk. Factories producing the clinical product must pass audits for their preparation protocols, driven by a blend of science and regulatory vigilance learned through decades of careful scale-up.
Nafamostat Methanesulfonate takes on several identities in chemical research. It can undergo hydrolysis in the body, splitting into metabolites that researchers follow patiently in pharmacokinetics studies. Modifications of the amidine group or tweaks to the aromatic rings create analogues with slightly different biological footprints — small changes, big impact for future drug discovery. This compound remains chemically reactive in formulations, requiring precise pH management to prevent rapid degradation. Medicinal chemists, familiar with its core, understand how these changes open fresh territory for protease inhibitor research, especially against new disease targets.
In medical literature, Nafamostat Methanesulfonate may also show up as FUT-175. Its chemical registry numbers guide procurement and research communication, making it unmistakable in the cold world of clinical supply chains. Hospitals in Japan and South Korea know it as a generic or branded product under the names Fusan and Nafabios. For the new researcher or pharmacy tech, those names crop up regularly in hospital formularies and on order sheets, often right beside older anticoagulants, a mark of its lasting trust in medical settings.
Safety practices for Nafamostat Methanesulfonate leave no room for error. Clinics use calibrated pumps for infusions, monitoring vital signs in real-time to catch the rare but serious risks of hypersensitivity or anaphylactic reactions. Technicians wear personal protective gear to block skin or inhalation exposure, and protocols demand careful cleanup of spills due to the compound’s biological activity at even low concentrations. Waste disposal policies follow hazardous chemical standards, tying environmental and workplace safety to a drug that shows up in only the most serious clinical episodes. For medical teams, the safety checklists and recurring staff training never let up, reflecting the dual-edged nature of a powerful anticoagulant.
Hospitals lean on Nafamostat Methanesulfonate during situations where blood clotting can swing out of control: cardiopulmonary bypass, hemodialysis, and extracorporeal membrane oxygenation (ECMO). Japanese ICUs turn to this drug in pancreatitis and disseminated intravascular coagulation, recording decades-long experience with controlled studies and case reports. More recently, the COVID-19 pandemic breathed new life into research for anticoagulants that might blunt viral entry or severe inflammation, and Nafamostat’s name surfaced again. Rare off-label uses, like in certain cancer therapies, help underline its flexible, but always regulated, clinical role.
The early work focused on clotting and bleeding, but research teams have kept busy chasing new signals. Basic science now targets the broader family of serine proteases, expanding possible uses to organ transplants, inflammation, and even certain viral infections. Pharmacologists continue probing metabolic fate in diverse patient groups, measuring how genetic backgrounds, age, and health change the drug’s action and risk profile. Industry partners have poured resources into finding analogues with fewer side effects, chasing the balance between rapid clot control and long-term tolerance. Each breakthrough adds to clinical guidelines, with regulatory authorities reviewing new evidence to adjust best practices around the world.
Toxicologists have mapped out the risks tied to Nafamostat Methanesulfonate use. Animal studies sketch dose-response curves, identifying the fine line between a therapeutic window and harmful exposures. Patient studies still report hypersensitivity, rare but serious, along with bleeding complications that keep teams on high alert. Chronic exposure models test for organ-specific toxicity, scouring for subtle changes that long-term use might hide. Published data provide early warning signs, and post-market surveillance flags incidents that eluded initial trials. Careful toxicology work steers hospitals toward safer infusions and calls for constant education on early symptom recognition among caregivers and patients alike.
Scientists see plenty of ground left to cover for Nafamostat Methanesulfonate. COVID-19 opened new doors, with researchers examining the compound’s power to limit viral spike protein activity and tamp down runaway inflammation in sick lungs. Chemists continue crafting analogues, dreaming of newer generations that could treat clotting disorders outside the old boundaries. Some biotech firms eye oral or depot formulations, lowering the hospital barrier for use. Regulatory agencies remain cautious, demanding clear data before adding to the drug’s label, and clinicians balance hope for new indications with hard lessons learned from tough patient cases. The public conversation grows louder about affordable access, supply chain durability, and the ethical questions facing old, life-saving drugs finding new purpose in an unpredictable healthcare landscape.
Plenty of folks haven’t run across the name Nafamostat Methanesulfonate in their daily lives. This compound pops up mainly in hospital settings, especially across parts of Asia like Japan and South Korea. It’s not a household painkiller or a vitamin supplement. Instead, this drug steps in where blood clotting and inflammation become life-or-death problems.
Nafamostat acts as a strong protease inhibitor. In plain terms, it keeps certain enzymes in our bodies from going haywire. Doctors reach for this drug during procedures like hemodialysis—treatments for people whose kidneys have tapped out. Patients hooked up to dialysis machines run a real risk for clots forming in those delicate tubes. Blood thinners like heparin get a lot of attention, but Nafamostat offers a gentler touch when bleeding is already an issue. This became important for some of my older relatives who went through dialysis. Sometimes the usual blood thinners sent their blood counts tumbling. For them, doctors tried Nafamostat to strike a middle ground.
Acute pancreatitis brings a special kind of agony. The pancreas releases digestive enzymes, and sometimes these turn on the organ itself, causing severe inflammation. Nafamostat can quiet those runaway enzymes, slowing the damage. During my internship at a gastroenterology clinic, I watched as physicians weighed the benefits of this drug for folks with sudden pancreatic attacks. For patients at risk of complications from standard treatments, doctors sometimes trusted Nafamostat to curb the worst symptoms.
Medical science loves to repurpose existing drugs. The story of Nafamostat recently took a turn as researchers explored its ability to fight viruses, including the coronavirus behind COVID-19. The compound blocks the entry of viruses into cells, at least in lab experiments. In 2020, the rush to find COVID-19 treatments spotlighted older medicines, especially those like Nafamostat that already played a role in reducing inflammation or clotting. Early studies out of Japan and Germany hinted at a possible benefit, though large trials never materialized. Still, the drug offered hope in situations where few options existed.
No medicine works miracles without risk. Nafamostat can cause trouble itself—lowering blood pressure and bringing on dangerous potassium shifts. Not every hospital stocks it, especially outside of Asia. Its short half-life demands constant attention and careful dosing by experienced clinicians.
While newer blood thinners and inflammation fighters crowd pharmacy shelves, Nafamostat hasn’t disappeared. People with tricky medical histories—who can’t take common anticoagulants or who spiral downward in acute inflammation—count on it. Physicians facing difficult cases want a whole toolbox, not just flashy new products.
Healthcare systems outside of Japan and South Korea might do well to keep an eye on how these countries use the drug. Maybe this is an example of how borrowing solutions from somewhere else fills in gaps at home. For patients up against sepsis, clotting disorders, or the worst pancreatitis, choices matter—and sometimes, an old drug like Nafamostat gives just enough of an edge.
People often ask what to expect from taking a medicine like nafamostat methanesulfonate. This drug acts as an anticoagulant, used in some critical care settings. My own time working with medical teams and patients taught me the side effect list isn’t just a technicality. These stories come out in everyday hospital life—sometimes quietly, other times in bright red alerts on a monitor or a chart.
The biggest risk on everyone’s mind with nafamostat involves bleeding. This medication stops clots, so nosebleeds, bruises, or gum bleeding pop up frequently in reports. Excessive bleeding from routine blood draws or even in stool shows up in both Japanese and international post-marketing records. Medical journals make it clear that, in critical settings, even a little extra bleeding can cause anxiety for patients and staff. Anyone who takes this medicine needs close checking—having seen people go through this, I value a thorough conversation upfront between doctors, nurses, and families about these risks.
Healthcare workers talk about itchy skin or rashes soon after starting nafamostat. Serious reactions, called anaphylaxis, appear rarely but can move fast. Urticaria, which are raised hives, and redness (erythema) add to the discomfort. In one unit, I met a fellow who broke out in sudden hives—nurses caught it quickly, stopped the medicine, and thankfully he recovered. These aren’t textbook risks; they’re real for people with histories of allergies, so both patients and providers watch these cases more closely.
Low blood pressure can turn a stable patient into a new concern for the care team. Sometimes, after starting nafamostat, the pressure drops enough to cause dizziness or sweaty skin. Hospital teams often check vitals more often for this reason. It’s not a matter of just numbers—in frail or older adults, even mild blood pressure drops can slow recovery or put them at risk of falling.
People getting nafamostat see changes in test results like aPTT or thrombin time. Those results sometimes look like the patient’s blood will take too long to clot, raising alarms for doctors. In a busy hospital or dialysis setting, clear communication between lab and clinical teams means better, safer care. A close friend, a dialysis nurse, often worried over patients’ lab swings, asking for timely updates to avoid hidden bleeding or clotting concerns.
Blood potassium drops in some patients, showing up as muscle cramps or weakness. Nurses pick up on these shifts by listening closely to patient concerns and not just checking lab slips. Replacing potassium or adjusting other medicines often keeps things safe. These stories underline why a hands-on approach works better than treating numbers in isolation.
Good care comes from teams who talk with patients, listen to small changes, and check labs often. I’ve found that when everyone has a clear plan—watch for bleeding, monitor for allergy signs, stay alert to blood pressure swings—patients fare better and feel safer. Open, simple explanations help people speak up early, making serious side effects less scary and easier to handle. This approach, baked into good hospital practice, gives patients more control and lets healthcare staff catch trouble before it grows.
Nafamostat methanesulfonate sits in hospital pharmacies as an anticoagulant and protease inhibitor, a small-molecule drug with roots in Japan and South Korea. Most folks don’t spot it in their medicine cabinets. To deliver it safely, hospitals rely on intravenous infusion. This isn’t your average pill you grab with a glass of water in the morning. The IV route means doctors and nurses control the dosage closely, offering adjustments on the fly. Blood thinners like this can tip patients toward bleeding if not handled right, so real-time oversight makes sense.
In my own time watching care teams manage acute pancreatitis and patients on dialysis, I’ve seen the value of drugs that get into the bloodstream immediately. Tablets or capsules pass through the stomach, liver, and intestines, losing some kick along the way. With naframostat, clinics want a predictable effect and fast action, especially for life-threatening clots or inflammation. By feeding it through a vein, you cut straight to the chase.
Hospital protocols line up the IV bags, and nurses set the infusion rate by machine or drip line. It can go through a peripheral vein in the arm, or sometimes a central line if a patient’s in the ICU for a while. Teams track the patient’s clotting numbers and electrolytes, aiming to stop complications before they start.
In real practice, side effects aren’t just risks you read in a textbook. IV-nafamostat brings its own set of worries—patients can have drops in blood pressure or react with allergic symptoms. Bleeding ranks high on everyone’s list. Most hospitals set up regular rounds to check labs and keep watch for odd bruising or sudden pain, lessons learned from decades dealing with older blood thinners.
Families sometimes ask why doctors don’t try oral alternatives. Some medicines suit oral or subcutaneous shots, but nafamostat does its job as a continuous drip because the gut chews it up too fast. Popping a pill wouldn’t get enough drug into circulation before the liver breaks it down. Doctors opt for IV since it delivers everywhere it’s needed—fast.
South Korea and Japan made nafamostat a staple for conditions like disseminated intravascular coagulation and pancreatitis. Some countries gave it a second glance during the COVID pandemic, hoping it could dampen runaway inflammation and blood clotting seen in the sickest patients. Early research posts some hope, though larger trials mean a proper answer will take time.
The path from drug to vein to recovery depends on more than just the medicine—it’s the team, the setup, and the close-eyed vigilance in the hours after giving the infusion. For anyone sitting with a loved one in the hospital, knowing the why behind this method helps. Careful IV use lowers the chance of complications, unlike oral routes that can’t give the same tight control. Hospitals back up their protocols with steady research, seeking fewer side effects without giving up the benefits that make nafamostat a trusted tool in tough cases.
Nafamostat Methanesulfonate, a drug used for its anticoagulant and anti-inflammatory effects, shows up most often in hospital settings. Doctors reach for it in cases like acute pancreatitis and during procedures involving extracorporeal circulation. It’s potent—fast acting, short half-life, and carries a real punch in terms of effect. Working with this medication at the bedside, I’ve seen impressive results for patients who truly needed it, but I’ve also witnessed what happens if the wrong person gets it. That’s where knowledge about contraindications really matters.
This drug works by inhibiting a range of enzymes, including those involved in blood clotting. Because of this, folks with active bleeding absolutely cannot risk this therapy. Someone already dealing with a gastrointestinal or cerebral bleed would risk a worsening hemorrhage. Even mild cases, like nosebleeds or gum bleeding, could end up much worse.
People with severe liver dysfunction fall into a high-risk group too. Liver problems alter how the body processes drugs and manages coagulation. In these cases, tiny missteps can end in disaster, and nafamostat can push delicate systems over the edge.
Nafamostat also poses real dangers in those who have had allergic reactions to it or drugs in its class. Even if someone’s only had a mild rash after a previous dose, another exposure could mean anaphylaxis or hives so severe they need steroids and even intubation.
The package inserts and clinical studies underline what practitioners encounter. Reports from Japan—where this drug is more common—show that patients with a known history of hypersensitivity to nafamostat can suffer from severe allergic reactions in as little as a few minutes. Extensive bleeding complications have popped up in those with underlying coagulation disorders. Researchers tracked platelet drops and abnormal bleeding times in a sizable minority of treated individuals, reinforcing that anyone with a history of bleeding disorders or current thrombocytopenia should usually steer clear unless the benefit absolutely outweighs risk.
Another layer of caution comes from the fact that renal dysfunction slows drug elimination. Accumulation means higher blood levels, which amplifies both bleeding and other adverse effects, so dose adjustments or outright avoidance often make sense in chronic kidney disease. Clinical trials rarely include these patients, so doctors end up with less data and rely on case reports and their own judgment.
Hospitals and pharmacies need strong screening protocols before administering nafamostat. Electronic health records flagging allergies, current bleeding, or marked hepatic or renal impairment can save lives. For the patient at the center of care, education matters too. Maybe it’s a five-minute conversation about what symptoms to watch for, or a take-home card listing the signs of bleeding or allergy reactions. Frontline clinicians could also benefit from refresher courses on recognizing which patients fall in the danger zone.
Broader awareness among non-specialists would help. Primary care doctors, ER doctors, and pharmacists ought to know this agent’s contraindications as well as specialists do. The risk here isn’t theoretical—lives hang in the balance every year. Investigators studying new clinical uses for nafamostat must stay rigorous with inclusion and exclusion criteria, and keep reporting adverse events.
Nafamostat offers real hope for a handful of difficult situations, but only for the right patient. Knowing the major contraindications—bleeding disorders, liver dysfunction, hypersensitivity, and severe renal impairment—can make the difference between a good outcome and a tragedy. The best patient care comes from teams who respect these boundaries, talk with their patients, and keep learning together.
Nafamostat methanesulfonate stands out as a strong anticoagulant, often used in clinical settings for managing blood clotting during procedures like hemodialysis. Practical experience shows that this drug demands careful handling. Medical professionals trained in its use usually work behind the scenes to reduce the risk of unwanted bleeding. Working in hospitals, I've seen skilled nurses watch patients like hawks after a dose, checking vitals and scanning for any odd bruises or sudden drops in blood pressure. People receiving this medication often can't tell if blood is too thin until it's too late, so vigilance from the care team does the heavy lifting.
The most pressing risk with nafamostat methanesulfonate comes from unpredictable bleeding. One busy shift, a patient on dialysis started showing blood in his urine and gums. The team caught it early because we made a point of communicating and checking labs frequently. Bloodwork and clotting tests are not optional; they're the first sign when things are sliding off track. Allergy is another real concern, though rare. Even with preventive measures, a person could suddenly break out in hives or experience trouble breathing, requiring immediate intervention. In my own practice, having epinephrine and resuscitation gear within arm's reach eased my mind a little, but every dose came with a sense of responsibility.
My work with patients from different backgrounds taught me that not all bodies handle drugs the same. Those with kidney or liver issues usually need closer attention since these organs process many medications. Nafamostat can interact with other blood thinners or drugs that affect clotting, sometimes leading to chaos in the body. Double-checking medication lists before starting treatment protects patients from dangerous combinations. It's tempting to trust the system, but as nurses and pharmacists, we catch mistakes computers might miss, especially with complex regimens.
Limiting complications starts with clear guidelines and real teamwork. Good practice means giving the right dose, adjusting for a patient’s health status, and never skipping routine checks. In my experience, documenting every aspect — from dosage to signs of side effects — creates a safety net. Training sessions at my hospital focused on case studies rather than dry theory, and that’s what helped the lessons stick. Communicating with both patients and families builds trust, especially when the risk of severe side effects is higher than with common medications.
Hospitals need to invest in regular skills refreshers and standardized protocols. I've seen many errors avoided thanks to a simple checklist and open lines of communication between nurses, doctors, and pharmacists. Publishing case studies and encouraging incident reviews help everyone learn from near misses. For patients, education is power. Folks who understand what to watch for—unusual bruising, confusion, trouble breathing—can alert the team early. With so much on the line, no one can afford to let their guard down, even for a moment.
| Names | |
| Preferred IUPAC name | 4-guanidinobenzoic acid, 6-amidino-2-naphthyl ester, methanesulfonate |
| Other names |
FUT-175 Futhan Nafamostat mesilate Nafamstat mesilate Nafamostat mesylate Nafamostat methylsulfonate Nafamostat methanesulfonic acid salt Nafamostat hydrochloride |
| Pronunciation | /naˈfæməstæt ˌmɛθeɪnˈsʌlfəˌneɪt/ |
| Identifiers | |
| CAS Number | [82956-11-4] |
| Beilstein Reference | 1093375 |
| ChEBI | CHEBI:61346 |
| ChEMBL | CHEMBL2105937 |
| ChemSpider | 22228820 |
| DrugBank | DB06210 |
| ECHA InfoCard | 100.219.493 |
| EC Number | 3.4.21.36 |
| Gmelin Reference | 1192219 |
| KEGG | D08210 |
| MeSH | D016692 |
| PubChem CID | 448601 |
| RTECS number | RNK8312Q6Z |
| UNII | 94M7G14Y3U |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID5047343 |
| Properties | |
| Chemical formula | C21H25N5O8S2 |
| Molar mass | 539.53 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.49 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -2.2 |
| Acidity (pKa) | pKa = 8.2 |
| Basicity (pKb) | 5.92 |
| Magnetic susceptibility (χ) | -48.5e-6 cm³/mol |
| Dipole moment | 5.75 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 302.6 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | B01AD11 |
| Hazards | |
| Main hazards | Causes serious eye damage. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS05, GHS06, GHS08 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P280, P302+P352, P305+P351+P338, P310 |
| NFPA 704 (fire diamond) | NFPA 704: 2-3-2 |
| Flash point | > 259.1 °C |
| Lethal dose or concentration | LD50 mouse (intravenous): 14 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous LD50 = 62 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 6 to 9 mg/kg/day (as continuous intravenous infusion) |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Gabexate Camostat FUT-175 Sivelestat Aprotinin |
